Comparative Pharmacology
Head-to-head clinical analysis: BOSENTAN versus TRACLEER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSENTAN versus TRACLEER.
BOSENTAN vs TRACLEER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Endothelin receptor antagonist; blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors, inhibiting vasoconstriction and proliferation.
Bosentan is a dual endothelin receptor antagonist (ERA) that blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors in pulmonary vascular smooth muscle and endothelium, reducing vasoconstriction and cell proliferation.
62.5 mg orally twice daily for 4 weeks, then increase to maintenance dose of 125 mg twice daily.
Initial: 62.5 mg twice daily orally for 4 weeks, then increase to maintenance: 125 mg twice daily orally.
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours in healthy adults, but prolonged in patients with hepatic impairment (up to 21 hours in Child-Pugh Class A and B).
Clinical Note
moderateBosentan + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Bosentan."
Clinical Note
moderateBosentan + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Bosentan."
Clinical Note
moderateBosentan + Torasemide
"Bosentan may increase the hypotensive activities of Torasemide."
Clinical Note
moderateBosentan + Estrone sulfate
Terminal elimination half-life is approximately 4-5 hours in healthy adults. In patients with pulmonary arterial hypertension, half-life may be slightly prolonged (up to 6-8 hours) due to reduced clearance.
Primarily biliary excretion (≥50% as unchanged drug) with fecal elimination; renal excretion accounts for <3% of unchanged drug.
Primarily hepatic metabolism (CYP2C9 and CYP3A4) with biliary excretion of unchanged drug and metabolites. Renal excretion of unchanged drug is negligible (<1%). Fecal excretion accounts for ~75% of total clearance, with ~25% excreted in urine as metabolites.
Category D/X
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist
"The serum concentration of Estrone sulfate can be decreased when it is combined with Bosentan."